Targeting high Aurora kinases expression as an innovative therapy for hepatocellular carcinoma
Authors:
Open Access
- 2 March 2017
- journal article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (17) , 27953-27965
Abstract
Targeting high Aurora kinases expression as an innovative therapy for hepatocellular carcinoma Targeting high Aurora kinases expression as an innovative therapy for hepatocellular carcinomaKeywords
This publication has 31 references indexed in Scilit:
- Hippo Pathway in Organ Size Control, Tissue Homeostasis, and CancerCell, 2015
- YAP controls retinal stem cell DNA replication timing and genomic stabilityeLife, 2015
- The emerging roles of YAP and TAZ in cancerNature Reviews Cancer, 2015
- The AURORA initiative for metastatic breast cancerBritish Journal of Cancer, 2014
- Small Molecule R1498 as a Well-Tolerated and Orally Active Kinase Inhibitor for Hepatocellular Carcinoma and Gastric Cancer Treatment via Targeting Angiogenesis and Mitosis PathwaysPLOS ONE, 2013
- Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantationEuropean Journal of Gastroenterology & Hepatology, 2013
- The mitotic kinase Aurora-A promotes distant metastases by inducing epithelial-to-mesenchymal transition in ERα+ breast cancer cellsOncogene, 2013
- Hepatocellular carcinomaThe Lancet, 2012
- Aurora kinase inhibitors: novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemiasLeukemia, 2010
- The selective Aurora B kinase inhibitor AZD1152 as a novel treatment for hepatocellular carcinomaJournal of Hepatology, 2010